BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results

BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results


BioCryst Pharmaceuticals, Inc. announced today financial results for the fourth quarter and full year ended December 31, 2016. In a separate press release issued earlier today, BioCryst announced positive results from an interim analysis of its APeX-1 clinical trial of BCX7353 for the treatment of HAE attacks.



from Biotech News